1. Home
  2. FEBO vs CALC Comparison

FEBO vs CALC Comparison

Compare FEBO & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fenbo Holdings Limited

FEBO

Fenbo Holdings Limited

N/A

Current Price

$1.06

Market Cap

11.8M

Sector

N/A

ML Signal

N/A

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.64

Market Cap

9.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEBO
CALC
Founded
1993
2011
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
9.7M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
FEBO
CALC
Price
$1.06
$0.64
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
2.5K
123.8K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.30
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$2.07
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.46
52 Week High
$1.46
$7.20

Technical Indicators

Market Signals
Indicator
FEBO
CALC
Relative Strength Index (RSI) 41.70 46.79
Support Level $1.04 $0.50
Resistance Level $1.33 $0.78
Average True Range (ATR) 0.06 0.06
MACD -0.00 0.01
Stochastic Oscillator 0.06 42.97

Price Performance

Historical Comparison
FEBO
CALC

About FEBO Fenbo Holdings Limited

Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: